Overview
INKT market data
Price History
INKT price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.65 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.53 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -3,449.3% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $8.48 – $18.17 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $54.6M · P/B 6.29.
Company News
MiNK Therapeutics Q2 2026 Earnings Call: Complete TranscriptBenzinga · Aug 13, 2026, 1:29 PM
8-K filing — MiNK Therapeutics, Inc. (INKT)SEC EDGAR · Aug 13, 2026, 11:40 AM
MiNK Therapeutics Announces Launch Of Paid International Named-Patient Access Program For agenT-797 In Brazil With Orphan Drug ConsultingBenzinga · Aug 13, 2026, 11:33 AM
MiNK Therapeutics Says First Patients In Randomized Phase 2 C-1300-02 Trial Of agenT-797 Alive At Day 28 With Improved Oxygenation, ARDS Resolution, Vasopressor LiberationBenzinga · Aug 13, 2026, 11:33 AM
MiNK Therapeutics Q2 EPS $(0.62) Misses $(0.60) EstimateBenzinga · Aug 13, 2026, 11:32 AM
MiNK Therapeutics Says First Patients Treated With agenT-797 In Phase 2 Severe Hypoxemic Pneumonia Trial Alive At Day 28 With Improved Oxygenation, Infection ControlBenzinga · Aug 6, 2026, 4:09 PM
A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million CompanyBenzinga · Jun 2, 2026, 2:15 PM
MiNK Therapeutics shares are trading higher. The company announced that the first patient has been dosed in its randomized Phase 2 clinical trial evaluating agenT-797 with standard of care vs placebo with SOC in patients with severe acute lung injury and critical illness.Benzinga · May 28, 2026, 3:22 PM
MiNK Therapeutics Announces First Patient Dosed In Randomized Phase 2 Clinical Trial Evaluating Agent-797 With SOC Vs Placebo With SOC In Patients With Severe Acute Lung Injury And Critical IllnessBenzinga · May 28, 2026, 1:10 PM
MiNK Therapeutics Presents New Clinical, Translational Data On Agent-797 Showing Pathogen Suppression, Lung Immune Restoration And Tissue Repair Activation, Supporting Ongoing Phase 2 Trial, At ATS 2026Benzinga · May 20, 2026, 3:15 PM